StockData
INSMED Inc logo

INSMED Inc (INSM) stock

INSMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 8/30100% above fair value
$122.88+1.72 (+1.42%)

Close on Nov 16, 2026Market cap $26.96BP/E –Yield –

Insmed r&d expenses

Research and development expenses are spending on new products and technology.

Insmed's R&D Expenses for the twelve months ending Sep 30, 2026 was $944.39M, up 35.7% year over year. For fiscal 2025 it was $771.09M, up 28.9% from the year before. Over ten years it grew 26.4% a year on average. The highest annual figure on record is $771.09M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$771.09M+28.9%
FY2024Dec 31, 2024$598.37M+4.8%
FY2023Dec 31, 2023$571.01M+43.6%
FY2022Dec 31, 2022$397.52M+45.7%
FY2021Dec 31, 2021$272.74M+50.6%
FY2020Dec 31, 2020$181.16M+37.5%
FY2019Dec 31, 2019$131.71M-9.3%
FY2018Dec 31, 2018$145.28M+32.4%
FY2017Dec 31, 2017$109.75M-10.6%
FY2016Dec 31, 2016$122.72M+65.2%
FY2015Dec 31, 2015$74.28M+31.9%
FY2014Dec 31, 2014$56.29M+27.1%
FY2013Dec 31, 2013$44.28M+48.7%
FY2012Dec 31, 2012$29.78M+4.0%
FY2011Dec 31, 2011$28.62M+508.7%
FY2010Dec 31, 2010$4.70M-48.9%
FY2009Dec 31, 2009$9.21M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$269.96M+44.8%
Q2 FY2026Jun 30, 2026$210.03M+18.5%
Q1 FY2026Mar 31, 2026$209.49M+37.3%
Q4 FY2025Dec 31, 2025$254.91M+41.8%
Q3 FY2025Sep 30, 2025$186.42M+23.6%
Q2 FY2025Jun 30, 2025$177.19M+20.7%
Q1 FY2025Mar 31, 2025$152.58M+26.0%
Q4 FY2024Dec 31, 2024$179.73M+31.2%
Q3 FY2024Sep 30, 2024$150.81M+38.2%
Q2 FY2024Jun 30, 2024$146.75M-25.5%
Q1 FY2024Mar 31, 2024$121.08M-5.3%
Q4 FY2023Dec 31, 2023$137.03M+9.8%
Q3 FY2023Sep 30, 2023$109.15M+9.3%
Q2 FY2023Jun 30, 2023$196.97M+122.5%
Q1 FY2023Mar 31, 2023$127.87M+51.6%
Q4 FY2022Dec 31, 2022$124.76M+63.4%
Q3 FY2022Sep 30, 2022$99.87M+42.0%
Q2 FY2022Jun 30, 2022$88.53M+36.9%
Q1 FY2022Mar 31, 2022$84.36M+37.4%
Q4 FY2021Dec 31, 2021$76.35M+12.6%
Q3 FY2021Sep 30, 2021$70.35M+69.9%
Q2 FY2021Jun 30, 2021$64.66M+80.9%
Q1 FY2021Mar 31, 2021$61.39M+69.7%
Q4 FY2020Dec 31, 2020$67.81M+107.8%
Q3 FY2020Sep 30, 2020$41.41M+20.6%
Q2 FY2020Jun 30, 2020$35.75M+6.6%
Q1 FY2020Mar 31, 2020$36.18M+16.0%
Q4 FY2019Dec 31, 2019$32.63M-18.3%
Q3 FY2019Sep 30, 2019$34.34M-13.1%
Q2 FY2019Jun 30, 2019$33.54M-6.1%
Q1 FY2019Mar 31, 2019$31.20M+3.7%
Q4 FY2018Dec 31, 2018$39.93M+17.6%
Q3 FY2018Sep 30, 2018$39.54M+48.2%
Q2 FY2018Jun 30, 2018$35.72M+32.9%
Q1 FY2018Mar 31, 2018$30.10M+35.2%
Q4 FY2017Dec 31, 2017$33.95M-38.1%
Q3 FY2017Sep 30, 2017$26.68M–
Q2 FY2017Jun 30, 2017$26.87M–
Q1 FY2017Mar 31, 2017$22.25M–
Q4 FY2016Dec 31, 2016$54.87M–

More Insmed figures

See a number that looks wrong?